Entries by gatekeeper

Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.

Emergex Appoints US Federal Government Experts The Conafay Group

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has appointed The Conafay Group, US Federal Government experts, to advise on the US healthcare landscape and policy and to provide introductions to help establish new business contacts.

Sir David King Joins Emergex’s Board of Directors

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Sir David King has joined Emergex’s Board as a Non-Executive Director.

Emergex Builds its Finance Team with Two New Recruits

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has built its Finance team and strengthening its operational capabilities.

Emergex Vaccines Awarded SBRI Contract by Innovate UK

Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that they have been awarded a £499,825 SBRI contract with the Department of Health/Technology Strategy Board, facilitated by Innovate UK, the UK’s Innovation Agency. The ‘Vaccines for Global Development – Preclinical’ grant proceeds will be used to advance the Zika and multivalent filovirus (Ebola and Marburg) vaccine programmes.

Emergex Vaccines Approved as Member of the Social Stock Exchange

Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announces that they have been approved as a member of the Social Stock Exchange, society’s market for impact investing. This follows the ratification of Emergex’s impact report by the Social Stock Exchange’s independent Admissions Panel.